Search clinical trials for: Resorbable polymer

Total 1816 results

The First Affiliated Hospital of Xiamen University

Not yet recruiting

Maintenance Therapy After Platinum-containing Chemotherapy in Patients With Recurrent Ovarian Cancer

Ovarian Cancer
MedSIR

Not yet recruiting

Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic Progression (ANALLISA)

Ovarian Cancer | Oligometastatic Disease | Serous Ovarian Tumor
Pamela Munster
National Cancer Institute (NCI)

Recruiting

Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

BRCA1 Mutation | BRCA2 Mutation | PALB2 Gene Mutation | ATM Gene Mutation | BRCA Mutation | Checkpoint Kinase 2 Gene Mutation

United States
Haider Mahdi
GlaxoSmithKline; Zenith Epigenetics

Recruiting

ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors

Ovarian Cancer | Recurrent Solid Tumors

United States
National Cancer Centre, Singapore
Merck Sharp & Dohme LLC; National Medical Research Council (NMRC), Singapore

Not yet recruiting

Pembrolizumab and Olaparib Treatment for Relapsed or Refractory Peripheral T-Cell Lymphoma (POLAR)

Refractory Peripheral T-Cell Lymphoma | Relapsed Peripheral T-Cell Lymphoma

Singapore
Guangxi Medical University

Not yet recruiting

Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma | High Grade Serous Adenocarcinoma of Ovary

China
Shanghai Yizhong Pharmaceutical Co., Ltd.

Recruiting

Paclitaxel Polymeric Micelles for Injection Versus TPC on the Treatment of HER2-negative Metastatic Breast Cancer (MBC).

Metastatic Breast Cancer (MBC)

China
University Hospital, Tours

Not yet recruiting

Development and Qualification of Methods for Analyzing the Mucosal Immune Response to COVID-19 (MUCOVID)

Certain Disorders Involving the Immune Mechanism

France
Peking University Cancer Hospital & Institute

Recruiting

Niraparib Maintenance in HRD-Positive Advanced Ovarian Cancer Following Front-Line Chemotherapy + Bevacizumab (BRAND)

Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma

China
M.D. Anderson Cancer Center
Mirati Therapeutics Inc.

Recruiting

Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers

Advanced Solid Tumor | Non-small Cell Lung Cancers

United States
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer

Breast Neoplasms

China
National Institute of Allergy and Infectious Diseases...

Not yet recruiting

A Safety Assessment of Oral Letermovir in Infants With Symptomatic Congenital Cytomegalovirus

Congenital Cytomegalovirus Infection
University of Southern Denmark
Roche Diagnostics

Recruiting

Point of Care Polymerase Chain Reaction (PCR) Diagnostics of Respiratory Tract Infections in General Practice

Respiratory Tract Infections

Denmark
Affiliated Hospital of Nantong University

Not yet recruiting

CYP1A2, ABCB1, CYP2C9 and Plasma Concentration of Agomelatine in Adult Patients With Depression

Depression | Polymerase Chain Reaction | Polymorphism, Genetic | CYP1A2 Polymorphism | Plasma Concentration | CYP2C9 Polymorphism
Mario Negri Institute for Pharmacological Research
AstraZeneca

Recruiting

First Line Treatment With Olaparib in Combination With Bevacizumab in HRD Positive Patients (IOLANTHE)

Carcinoma, Ovarian Epithelial

Italy
Alexander B Olawaiye, MD
AstraZeneca

Recruiting

Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known Homologous Recombination Deficiency

Ovarian Cancer

United States
Gustave Roussy, Cancer Campus, Grand Paris
Merck Sharp & Dohme LLC

Not yet recruiting

Study Evaluating Pembrolizumab +/- Olaparib in TLS Positive Selected Resectable STS Followed by Adjuvant Pembrolizumab (NeoSarc)

Cancer

France
AstraZeneca
Daiichi Sankyo

Recruiting

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

Breast Cancer

Spain, China, United States, Italy, United Kingdom, Korea, Republic of, Belgium, France, Germany, Poland, Japan, Vietnam, Canada, Brazil, India, Malaysia, Taiwan, Thailand, Australia, Austria, Turkey, Hong Kong, Bulgaria, Switzerland, H... and more
Istituto Ortopedico Rizzoli

Recruiting

Arthrorisis of the Subtalar Joint With a Polymeric Endorthesis for Flexible Flatfoot Treatment During the Growth Age Prospective Evaluation

Flat Feet | Subtalar Arthrorisis | Growth Age

Italy
Genoss Co., Ltd.

Recruiting

Evaluation of Effectiveness and Safety of Abluminal Biodegradable Polymer Sirolimus-eluting Stent (GENCOMX)

Coronary Artery Disease | Percutaneous Coronary Intervention

Korea, Republic of
Jin Li

Not yet recruiting

Fluzoparib Combined With Apatinib in Relapsed Ovarian Carcinoma Maintenance Treatment

Relapsed Ovarian Cancer
The University of Texas Health Science Center,...
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Recruiting

Modernizing Perinatal Syphilis Testing

Syphilis

United States
Assiut University

Recruiting

Potential Role of Inflammasome NLRP3 And IL-1B Gene Expression in COVID-19 Patients: Impact of Ferretin and D -Dimer.

Inflammasome NLRP3 And IL-1B Gene Expression in COVID-19 Patients

Egypt
Azienda Ospedaliero-Universitaria di Modena

Recruiting

Olaparib in PALB2 Advanced Pancreatic Cancer (PALBOLA)

Metastatic Pancreatic Cancer | Advanced Pancreatic Cancer

Italy
GlaxoSmithKline

Recruiting

A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors

Neoplasms

United States, Canada
Ruijin Hospital

Recruiting

PARP Inhibition, Stereotactic Body Radiotherapy and Immunotherapy for Metastatic or Advanced Sarcoma (PRIMA) (PRIMA)

Sarcoma | Sarcoma,Soft Tissue | Sarcoma of Bone

China
University of Pennsylvania
Merck Sharp & Dohme LLC

Recruiting

Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients

Cytomegalovirus Infections | Transplant-Related Disorder

United States
Aesculap AG
B.Braun Surgical SA

Recruiting

STEELEX® Sternum Set + BONE WAX® + STEELEX® Electrode Set in Patients Undergoing Cardiac Surgery (STEADY)

Sternum Closure

Spain
Sun Yat-sen University

Not yet recruiting

First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer

Ovarian Cancer | Primary Peritoneal Cancer | High Grade Serous Adenocarcinoma of Ovary | High Grade Endometrioid Ovarian Cancer | Fallopian-tube Cancer

China
Sohag University

Recruiting

Angiotensin Converting Enzyme rs (1799752) Gene Polymorphism and Development of In-Stent Restenosis in Patients With Stable Coronary Artery Diseases in Sohag Hospital University.

Angiotensin Converting Enzyme rs (1799752) Gene Polymorphism and Development of In-Stent Restenosis in Patients With Stable Coronary Artery Diseases

Egypt
Maimónides Biomedical Research Institute of Córdoba
MERCK SHARP & DOHME DE ESPAÑA S.A.

Not yet recruiting

Efficacy of Letermovir in Preventing Cytomegalovirus (CMV) Infection in Lung Transplant Recipients vs. Valganciclovir. (LETERCOR)

Infections, Cytomegalovirus

Spain
Chongqing University Cancer Hospital

Not yet recruiting

A Clinical Study of Chemoradiotherapy Sequential Fluzoparib in Pan-solid Tumors

PARP Inhibitor for Esophageal Squamous Cell Carcinoma
Medtronic

Recruiting

Enlighten Study: The EV-ICD Post Approval Registry

Tachycardia | Ventricular Arrhythmia

United States, Switzerland, Spain, Netherlands, Finland, France, Germany, Denmark, Sweden, Czechia, United Kingdom, Belgium, Poland, Austria, New Zealand, Norway, Portugal, Kuwait, Greece, Hungary
The First Affiliated Hospital of Soochow University

Recruiting

Letermovir for the Prevention of CMV Infection in HSCT Recipients Based on the Outcome of mNGS

Hematopoietic Stem Cell Transplantation | CMV Infection

China
M3 Health
São Paulo State University

Not yet recruiting

Guided Bone Regeneration Using Polydioxanone (PDO) Membrane in Sockets After Tooth Extraction

Surgery, Oral
Central Taiwan University of Science and Technology

Recruiting

Preventing Pressure Injuries in Patients Undergoing Lumbar Spine Surgery

Pressure Injury

Taiwan
Taipei Medical University Hospital
Taipei Medical University; Panion & BF Biotech Inc.

Recruiting

Polymeric Microspheres vs Sculptra® in the Treatment of Moderate to Severe Nasolabial Folds

Nasolabial Fold Wrinkles

Taiwan
Acuity Polymers, Inc.

Not yet recruiting

Acuity 200™ (Fluoroxyfocon A) Orthokeratology Contact Lens for Overnight Wear (Acuity200OK)

Myopia

United States, Australia, New Zealand
Virginia Commonwealth University
Merck Sharp & Dohme LLC

Recruiting

De-novo Initiation of Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis in AA Kidney Trans Recip

CMV | Kidney Transplant; Complications

United States
Institute of Cancer Research, United Kingdom
Royal Marsden NHS Foundation Trust

Not yet recruiting

SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy (SOPRANO)

Ovarian Cancer Recurrent

United Kingdom
Jun Guo

Not yet recruiting

Fluzoparib in Combination With Camrelizumab and Temozolomide in Advanced Melanoma

Melanoma
Tianjin Medical University Cancer Institute and...

Recruiting

Study of Selinexor Combined With Olaparib in Relapsed/Refractory Extensive Stage Small Cell Lung Cancer

Extensive-stage Small Cell Lung Cancer

China
Rabin Medical Center

Not yet recruiting

Letermovir Prophylaxis for Cytomegalovirus (CMV) in Patients With Graft-versus-host Disease

CMV | Graft-versus-host-disease
Sunnybrook Health Sciences Centre
GlaxoSmithKline

Recruiting

Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer

Ovarian Cancer | Stage IV Ovarian Cancer | High Grade Ovarian Serous Adenocarcinoma | Stage III Ovarian Cancer

Canada
University Hospital, Bordeaux

Recruiting

Bacterial Sexually Transmitted Infections (STIs) Viability by Polymerase Chain Reaction (PCR) (VISTH)

Men Who Have Sex With Men

France
Sun Yat-sen University
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Recruiting

Phase Ib/II Study of Fluzoparib in Combination With Dalpiciclib in Patients With Locally Advanced or Metastatic Sarcoma

Sarcoma

China
University Medical Center Groningen

Not yet recruiting

OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults (OPTI-DOSE)

Renal Cell Carcinoma | Breast Carcinoma | Thyroid Carcinoma | Ovarian Carcinoma | Endometrium Carcinoma

Netherlands
AusDiagnostics Pty Ltd.

Not yet recruiting

Clinical Evaluation of SARS-COV-2 (COVID-19), Influenza and RSV 8-Well MT-PCR Panel for In Vitro Diagnostics

Respiratory Viral Infection
Cancer Institute and Hospital, Chinese Academy...
Beijing Jishuitan Hospital

Recruiting

Preoperative Moderately Fractionated IMRT for Locally Extremity or Trunk Sarcoma

Soft Tissue Sarcoma

China
Sun Yat-sen University

Not yet recruiting

Apatinib and Fluzoparib With or Without Adebrelimab in Previously-treated TP53-mutant Advanced Non-small Cell Lung Cancer

NSCLC | Non-small Cell Lung Cancer

China

Search clinical trials for: Resorbable polymer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Papua New Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations